论文部分内容阅读
BACKGROUND New direct-acting antivirals(DAAs)-based anti-hepatitis C virus(HCV)therapies are highly effective in patients with HCV infection.However,safety data are lacking regarding HCV treatment with DAAs and drugs for comorbidities.CASE SUMMARY Herein,